FINWIRES · TerminalLIVE
FINWIRES

Gyre Therapeutics Says China Regulator Accepts Application for Liver Fibrosis Drug

By

Gyre Therapeutics Inc (GYRE) said China's regulator accepted its new drug application for F351, a treatment for chronic hepatitis B-induced liver fibrosis.

The application, which received priority review status in March, marks "a significant milestone" in the program's path toward commercialization, the company said Tuesday in a statement.

In the US, Gyre has completed a Phase 1 trial evaluating the drug's safety and tolerability in healthy volunteers and plans to file an investigational new drug application by the end of 2026, with a Phase 2 trial to follow if cleared.

Gyre shares rose 1.4% in after-hours trading.

Related Articles

Wire

Alcoa to Invest $65 Million in Norway Aluminum Smelter to Include Recycled Content in Casting Process; Shares Up 4%

Alcoa (ASX:AAI) will invest $65 million to expand foundry production capabilities to include recycled content in the casting process at its Mosjøen aluminum smelter in Norway, according to a Tuesday statement from the company.The investment will expand and upgrade the Mosjøen casthouse, increasing production capacity by up to 75,000 metric tons.The project is expected to be completed in phases, with commissioning and ramp-up scheduled to progress throughout 2028, the company said.Alcoa's shares climbed 4% in recent trading on Tuesday.

ASX:AAI
Wire

BHP Group Hits Record High as Copper Prices Surge

Shares of BHP Group (ASX:BHP) rose around 3% in Tuesday trading and earlier hit a record high after copper prices closed at an all-time peak, lifting the miner's market value to AU$305 billion, as investors shrugged off geopolitical concerns related to the Iran conflict and the Strait of Hormuz.Copper rose 2.7% to settle at $13,943 per tonne on the London Metal Exchange, marking a record high close and surpassing its previous peak of $13,618.

ASX:BHP
Wire

Danaos Q1 Adjusted Earnings, Revenue Rise

Danaos (DAC) reported Q1 adjusted earnings late Monday of $6.72 per diluted share, up from $6.04 a year earlier.One analyst polled by FactSet expected $6.60.Revenue in the three months ended March 31 rose to $253.7 million from $253.3 million a year earlier.Two analysts surveyed by FactSet expected $236.5 million.The company kept its quarterly dividend at $0.90 a share, payable June 4 to stockholders of record May 26.Danaos shares rose 1% in after-hours trading.

$DAC